-- Actavis Completes Purchase of Serbia’s Zdravlje for $9.2 Million
-- B y   M i s h a   S a v i c
-- 2013-04-29T14:08:49Z
-- http://www.bloomberg.com/news/2013-04-29/actavis-completes-purchase-of-serbia-s-zdravlje-for-9-2-million.html
Actavis Inc. (ACT) , the world’s fourth
biggest maker of generic drugs, bought the entire equity of
 Serbia ’s FHI Zdravlje AD as small shareholders sold their stock.  Actavis started the buyout on Nov. 2 to acquire 26.7
percent of the company it didn’t own and completed it at the
cost of more than 7 million euros ($9.2 million), the company
said in an e-mailed statement today.  Leskovac, Serbia-based Zdravlje was bought in 2002 for 3.5
million euros. Actavis said it invested more than 50 million
euros in the plant, including the buyout.  To contact the reporter on this story:
Misha Savic in Belgrade at 
 msavic2@bloomberg.net   To contact the editor responsible for this story:
James M. Gomez at   jagomez@bloomberg.net  